Phase 2Recruiting
BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
- Sponsor
- Blue Blood Biotech Corp. (Industry)
- Enrolment
- 96 planned
- Conditions
- Diabetic Foot Ulcer
- Interventions
- BB-101
- Ages
- adults, older adults
- Registry
- NCT06383013
Full record on ClinicalTrials.gov
From the registry
This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.
Primary outcomes
- Efficacy Evaluation
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered